Merck price target lowered to $155 from $160 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Merck (MRK) to $155 from $160 and keeps a Buy rating on the shares. Heading into Q3 results, Merck has continued to…
Fiscal Year: January - December
Merck & Co., Inc. (MRK), listed on the NYSE, has a market capitalization of $365.88B. As of Oct 21, 2026, the stock is trading at $148.30 per share@else an unavailable price , offering investors a clear view of its current market value. Merck & Co., Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 116.51, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Merck & Co., Inc. also offers a dividend yield of 2.29%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Merck & Co., Inc. (MRK) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Merck & Co., Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Merck & Co., Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Merck & Co., Inc. is 22.78, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Merck & Co., Inc. (MRK) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Merck & Co., Inc. (MRK) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Merck & Co., Inc. (MRK) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Merck & Co., Inc.. To access the full SS Score, consider upgrading your subscription.
Merck & Co., Inc. is a significant player in the industry sector, with a market capitalization of $365.88B and a competitive P/E ratio of 116.51. Investors should compare these metrics with industry peers to gauge whether Merck & Co., Inc. is outperforming or underperforming within its sector.
Goldman Sachs lowered the firm’s price target on Merck (MRK) to $155 from $160 and keeps a Buy rating on the shares. Heading into Q3 results, Merck has continued to…
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.
Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex sy...
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Merck (MRK) & Co. announced that Paul Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will stand for election…
RAHWAY, N.J.--(BUSINESS WIRE)--Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be...
RBC Capital analyst Trung Huynh lowered the firm’s price target on Merck (MRK) to $145 from $150 and keeps a Sector Perform rating on the shares. The firm is reducing…
Citi raised the firm’s price target on Merck (MRK) to $145 from $125 and keeps a Neutral rating on the shares. The firm says the biopharma backdrop “remains constructive” into…
Merck (MRK) announced the first presentation of one-year results from the pivotal Phase 2b/3 Brunello trial evaluating remigromig, an investigational, potentially first-in-class tetravalent, tri-speci...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase ...
BofA lowered the firm’s price target on Merck (MRK) to $163 from $166 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview for…
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Merck (MRK) to $145 from $120 and keeps a Neutral rating on the shares. Increasing expectations for a 2027…
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.
Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck , ordering the drugmaker to halt the manufacture and sale of injectable Keytruda in eight Euro...
Morgan Stanley lowered the firm’s price target on Merck (MRK) to $177 from $179 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
Tempus (TEM) announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy bein...
Halozyme Therapeutics (HALO) announced that the specialized Dutch patent court of the Hague has found Merck (MRK) to be infringing one of its MDASE patents, EP 2,797,622 and ordered Merck’s…
JPMorgan raised the firm’s price target on Merck (MRK) to $165 from $150 and keeps an Overweight rating on the shares ahead of the Q3 report on October 29. The…
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29.
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 13.52B | 9.38% | Projected |
| 2027 | 14.79B | 9.38% | Projected |
| 2028 | 16.18B | 9.38% | Projected |
| 2029 | 17.69B | 9.38% | Projected |
| 2030 | 19.35B | 9.38% | Projected |
| 2031 | 20.90B | 8.01% | Projected |
| 2032 | 22.29B | 6.63% | Projected |
| 2033 | 23.46B | 5.25% | Projected |
| 2034 | 24.37B | 3.88% | Projected |
| 2035 | 24.98B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 18.10B | 1.00 | 18.10B |
| 2025A | 12.36B | 1.00 | 12.36B |
| 2026E | 13.52B | 1.07 | Login |
| 2027E | 14.79B | 1.15 | Login |
| 2028E | 16.18B | 1.24 | Login |
| 2029E | 17.69B | 1.33 | Login |
| 2030E | 19.35B | 1.43 | Login |
| 2031E | 20.90B | 1.54 | Login |
| 2032E | 22.29B | 1.65 | Login |
| 2033E | 23.46B | 1.78 | Login |
| 2034E | 24.37B | 1.91 | Login |
| 2035E | 24.98B | 2.05 | Login |
| Terminal | 2.05 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.